Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science

Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, January 31, 2023 (GLOBE NEWSWIRE) – Orange Grove Bio, a drug investment and development firm, today announced that it has established a new

Thani Al Zeyoudi attends World Investment Forum to accelerate investment in high-potential markets

The following excerpt was taken from dailyhunt.me — continue reading here. ABU DHABI, 19th October, 2023 (WAM) – Dr Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, has held a series of high-level meetings with global ministers on the fourth day of the 8th World Investment Forum (WIF), during which he

Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology

OGB Also Announces Key Appointments to Board of Senior Advisors and the Opening of New Headquarters The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, Sept. 28, 2023 (GLOBE NEWSWIRE)  Orange Grove Bio (OGB), a drug investment and development firm, today announced that Preservation Bio, one of the firm’s majority-owned subsidiaries, has been

Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships

Collaborations with Yonsei University Health System and Pohang University of Science and Technology Designed to Strengthen Biotech Entrepreneurial Ecosystem in South Korea The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships CINCINNATI, March 23, 2023 (GLOBE NEWSWIRE) — Orange Grove Bio, a

Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration

Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration to Strengthen Biotech Ecosystem and Support Development and Commercialization of Novel Therapeutics The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio, a drug investment and development firm, today announced the establishment of a strategic collaboration with the Magnuson

Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition

Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend

Orange Grove Bio Appoints Key Leadership & New Academic Collaboration

The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development

Orange Grove Bio and Cincinnati Children’s Hospital Medical Center Establish Collaboration

Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati

1819 Innovation Hub tenant inks key partnership with Korea VC firm

1819 Innovation Hub tenant inks key partnership with Korea VC firm The following excerpt was taken from TechOhio– continue reading here. A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration A biotech firm that moved its headquarters from New York to Cincinnati in

Leading Korean VC partners with USA’s Orange Grove

Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.